Anastrozole is used to treat breast cancer in postmenopausal women. It belongs to a class of drugs called aromatase inhibitors, which work by lowering the amount of estrogen the body makes [1]. By reducing estrogen levels, anastrozole can help slow or stop the growth of hormone-receptor-positive breast cancers [1][2].
How does anastrozole work in treating breast cancer?
Anastrozole functions by blocking the aromatase enzyme, which is responsible for converting androgens into estrogens [1][3]. In postmenopausal women, the primary source of estrogen is through this aromatase-mediated conversion. By inhibiting this process, anastrozole significantly decreases circulating estrogen levels, thereby depriving hormone-sensitive breast cancer cells of the estrogen they need to grow [1][2].
When is anastrozole prescribed?
This medication is typically prescribed as adjuvant therapy for early-stage, hormone-receptor-positive breast cancer in women who have gone through menopause [1]. It can also be used for metastatic breast cancer, meaning cancer that has spread to other parts of the body [2]. In some cases, it may be used to treat breast cancer in premenopausal women when combined with ovarian suppression [4].
What are the common side effects of anastrozole?
Patients using anastrozole commonly report hot flashes, joint pain (arthralgia), fatigue, and mood changes [1][5]. Other potential side effects include bone thinning (osteoporosis), vaginal dryness, and a reduced libido [1][5]. It is important for patients to discuss any concerning side effects with their healthcare provider.
How long do patients typically take anastrozole?
The duration of anastrozole treatment varies depending on the stage and type of breast cancer. For early-stage breast cancer, treatment often lasts for five years, though it may be extended in some situations [1]. For metastatic breast cancer, treatment continues as long as it is effective and tolerated [2].
What is the expected timeline for anastrozole to become more widely available or for generic versions to emerge?
Anastrozole is already available as a generic medication. The original patents for anastrozole have long since expired, allowing for the production and sale of generic versions by multiple pharmaceutical companies [6].
Are there alternative treatments for hormone-receptor-positive breast cancer?
Yes, other classes of drugs are used to treat hormone-receptor-positive breast cancer. These include selective estrogen receptor modulators (SERMs) like tamoxifen and other aromatase inhibitors such as letrozole and exemestane [7]. The choice of treatment depends on individual patient factors, menopausal status, and the specific characteristics of the cancer [7].
What is the difference between anastrozole and tamoxifen?
While both anastrozole and tamoxifen are used to treat hormone-receptor-positive breast cancer, they work through different mechanisms. Tamoxifen is a SERM that blocks estrogen receptors in breast tissue, while anastrozole is an aromatase inhibitor that reduces the body's production of estrogen [7]. Clinical trials have shown that aromatase inhibitors like anastrozole are generally more effective than tamoxifen in preventing recurrence in postmenopausal women with early-stage breast cancer [1][7].
Who manufactures anastrozole?
Anastrozole is manufactured by various pharmaceutical companies. Since it is a generic drug, multiple companies produce and market it under different brand names and as generics.
What is the cost of anastrozole?
As a widely available generic medication, anastrozole is generally affordable. The cost can vary depending on the manufacturer, dosage, and insurance coverage. Generic anastrozole can typically be purchased at a significantly lower price compared to its original branded form [6].
What are the patent details for anastrozole?
The original patents for anastrozole have expired. Patents for a drug typically last for 20 years from the filing date, but extensions and other legal maneuvers can affect the actual market exclusivity period [6]. Information on specific patent expiry dates for anastrozole can be found on patent databases and specialized pharmaceutical information websites, such as DrugPatentWatch.com [6].
What are the potential risks and concerns for patients taking anastrozole?
Beyond common side effects, a significant concern with aromatase inhibitors like anastrozole is the risk of osteoporosis and an increased chance of fractures due to decreased bone mineral density [1][5]. Regular bone density monitoring and calcium/vitamin D supplementation are often recommended [1][5]. Patients should also be aware of potential cardiovascular risks, although these are generally less common [5].
Can patients switch between different aromatase inhibitors?
Yes, patients may switch between different aromatase inhibitors (e.g., from anastrozole to letrozole) if one is not tolerated or if there is a clinical reason to do so, often under the guidance of an oncologist [7].
Are there any specific populations or conditions where anastrozole is not recommended?
Anastrozole is not recommended for premenopausal women unless used in conjunction with ovarian suppression, as it can be less effective and potentially harmful in this group [4]. It is also contraindicated in individuals with a known hypersensitivity to the drug [1].
What clinical data supports the use of anastrozole?
Numerous large-scale clinical trials, such as the Anastrozole, Tamoxifen, Alone, or in Combination (ATAC) trial, have established the efficacy of anastrozole in reducing the risk of breast cancer recurrence and improving survival rates in postmenopausal women with early-stage disease [1][8]. These studies have compared anastrozole to tamoxifen and placebo, demonstrating its benefits in reducing contralateral breast cancer incidence and distant recurrence [1][8].
How does anastrozole compare to other breast cancer treatments?
Compared to tamoxifen, anastrozole has demonstrated superior efficacy in preventing recurrence in postmenopausal women with early-stage hormone-receptor-positive breast cancer [1][8]. It is also used in the treatment of metastatic disease, where its effectiveness is evaluated based on tumor response and progression-free survival [2].
What are the regulatory approvals for anastrozole?
Anastrozole is approved by major regulatory agencies worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of hormone-receptor-positive breast cancer in postmenopausal women [1][2].
Sources:
[1] https://www.cancer.gov/drug-information/anastrozole
[2] https://www.mayoclinic.org/drugs-supplements/anastrozole-oral-route/description/drg-20061098
[3] https://www.drugbank.ca/drugs/DB00467
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271250/
[5] https://www.webmd.com/drugs/2/7640/anastrozole-oral/details
[6] https://drugpatentwatch.com/
[7] https://www.cancer.org/cancer/types/breast-cancer/treatment/drug-treatment-for-breast-cancer.html
[8] https://pubmed.ncbi.nlm.nih.gov/15473074/